Hipro Biotechnology attended WHX LAB Dubai 2026 held in Dubai from February 10th to 13th, 2026. As a premier lab and in vitro diagnostic (IVD) event in the Middle East region, WHX LAB Dubai has established itself as a leading platform for laboratory and healthcare professionals. It offers a unique opportunity for industry experts to connect, share knowledge, and discover the latest advancements in medical laboratory and diagnostic technology. Attendees include dealers and distributors, representatives from private and public hospitals, government officials, industry leaders, and other key stakeholders from the Middle East and across the globe.
The outstanding performance of Hipro at WHX LAB Dubai 2026 not only highlights the company's profound accumulation and innovative strength in the field of liquid phase platform, lateral flow platforms and microfluidics technology, but also further consolidates its influence in the Middle East market and reinforces its layout in the global IVD industry.
At present, Hipro’s liquid phase platform has won high recognition in the global market by virtue of its core technological advantages. Its flagship device HP-AFS/1 was the exceptional highlight in the fair, which attracted the eyes of many visitors and got highly praised from them with its own excellent performance and unique charm, such as high accuracy, wide linear range and high sensitivity. This fully proves Hipro's continuous R&D investment and technological innovation in the liquid phase platform, which provides more accurate and efficient solutions for clinical diagnosis and medical research over the world.
PalmF continued to attract wide attention at WHX LAB Dubai 2026. Its exquisite design perfectly fits the modern medical testing needs for speed and flexibility in the Middle East. At the same time, the high accuracy also ensures the reliability of the test results, providing strong support for telemedicine, emergency response and other scenarios. With the increasing emphasis on public health and safety in the region, the demand for portable testing equipment is growing steadily. PalmF’s outstanding performance undoubtedly laid a solid foundation for Hipro to further expand the Middle East portable diagnostic market.
.jpg "PHOTO_20260210_223135790(1).jpg")
Hipro’s DX-1 microfluidics immunoassay system also became a focal point of the exhibition, drawing in-depth attention from industry professionals. The system introduced the revolutionary 'reagent jet' liquid phase microfluidic platform, which enables fast and efficient detection of biological samples by precisely controlling the flow of small liquid volumes within microchannels. It significantly improves test sensitivity and specificity while reducing testing time, providing a game-changing solution for emergency and critical care settings in the region. This fully demonstrates Hipro's innovative strength in the field of microfluidics technology.
.jpg "PHOTO_20260213_070915242(1).jpg")
At the exhibition, many visitors were attracted by the convenience of Hipro’s ZOAN-Home Test. They not only appreciated the easy operation with integrated design, but also expressed great interest in this product that can be tested at home. These home use testing not only saves time, but also improves the privacy and convenience of testing At the same time, the ZOAN-Home Test has also been recognized by the industry, and its high sensitivity and accuracy greatly improve the reliability of the test results.
.jpg "PHOTO_20260210_22313600011(1).jpg")
During the exhibition, Hipro conducted in-depth communication with numerous customers over the world. These interactions not only deepened the basis of cooperation between the two sides, but also pointed out the direction for the company's future product performance improvement and software localization optimization. This customer-oriented development strategy helps Hipro to understand the international market demand more accurately, optimize the products and improve the user experience for local customers.
.jpg "44(1).jpg")
Hipro’s participation in WHX LAB Dubai 2026 reaffirms the company’s unwavering commitment to delivering high-quality IVD solutions and addressing global healthcare needs. Building on the momentum of this exhibition, Hipro will continue to increase R&D investment in core technologies, launch more diagnostic products tailored to regional market needs, and further deepen cooperation with global partners. The company will keep pushing the boundaries of innovation in the IVD industry, and strive to provide more accurate, efficient and user-friendly diagnostic solutions for clinical diagnosis and public health construction around the world, contributing to the development of global healthcare.
